Literature DB >> 27037933

Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.

Katherine M Byrd1, Chitra Subramanian2, Jacqueline Sanchez2, Hashim F Motiwala2, Weiya Liu3, Mark S Cohen2, Jeffrey Holzbeierlein3, Brian S J Blagg4.   

Abstract

Development of heat shock protein 90 (Hsp90) C-terminal inhibitors has emerged as an exciting strategy for the treatment of cancer. Previous efforts have focused on modifications to the natural products novobiocin and coumermycin. Moreover, variations in both the sugar and amide moieties have been extensively studied, whereas replacements for the coumarin core have received less attention. Herein, 24 cores were synthesized with varying distances and angles between the sugar and amide moieties. Compounds that exhibited good anti-proliferative activity against multiple cancer cell lines and Hsp90 inhibitory activity, were those that placed the sugar and amide moieties between 7.7 and 12.1 Å apart along with angles of 180°.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  C-terminal inhibitors; Hsp90; antitumor agents; luciferase refolding; medicinal chemistry

Mesh:

Substances:

Year:  2016        PMID: 27037933      PMCID: PMC4962924          DOI: 10.1002/chem.201504955

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  50 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

2.  Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Authors:  Takrima Sadikot; Megan Swink; Jeffery D Eskew; Douglas Brown; Huiping Zhao; Bhaskar R Kusuma; Roger A Rajewski; Brian S J Blagg; Robert L Matts; Jeffrey M Holzbeierlein; George A Vielhauer
Journal:  Assay Drug Dev Technol       Date:  2013-10-15       Impact factor: 1.738

3.  Identification and initial SAR of silybin: an Hsp90 inhibitor.

Authors:  Huiping Zhao; Gary E Brandt; Lakshmi Galam; Robert L Matts; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2010-12-28       Impact factor: 2.823

Review 4.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

5.  Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.

Authors:  Huiping Zhao; Gaurav Garg; Jinbo Zhao; Elisabetta Moroni; Antwan Girgis; Lucas S Franco; Swapnil Singh; Giorgio Colombo; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2014-10-14       Impact factor: 6.514

Review 6.  Organelle-specific Hsp90 inhibitors.

Authors:  Young Ho Seo
Journal:  Arch Pharm Res       Date:  2015-07-22       Impact factor: 4.946

7.  Modulation of Hsf1 activity by novobiocin and geldanamycin.

Authors:  Renaud Conde; Zachery R Belak; Manoj Nair; Ruth F O'Carroll; Nick Ovsenek
Journal:  Biochem Cell Biol       Date:  2009-12       Impact factor: 3.626

Review 8.  Heat shock protein 90: the cancer chaperone.

Authors:  Len Neckers
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

9.  (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.

Authors:  Zhengyu Yin; Ellen C Henry; Thomas A Gasiewicz
Journal:  Biochemistry       Date:  2009-01-20       Impact factor: 3.162

10.  KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.

Authors:  Shary N Shelton; Mary E Shawgo; Shawna B Matthews; Yuanming Lu; Alison C Donnelly; Kristen Szabla; Mehmet Tanol; George A Vielhauer; Roger A Rajewski; Robert L Matts; Brian S J Blagg; John D Robertson
Journal:  Mol Pharmacol       Date:  2009-09-09       Impact factor: 4.436

View more
  12 in total

1.  The quest for supernatural products: the impact of total synthesis in complex natural products medicinal chemistry.

Authors:  Zhi-Chen Wu; Dale L Boger
Journal:  Nat Prod Rep       Date:  2020-11-10       Impact factor: 13.423

2.  Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.

Authors:  Gaurav Garg; Leah K Forsberg; Huiping Zhao; Brian S J Blagg
Journal:  Chemistry       Date:  2017-11-03       Impact factor: 5.236

3.  Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.

Authors:  Leah K Forsberg; Mercy Anyika; Zhenyuan You; Sean Emery; Mason McMullen; Rick T Dobrowsky; Brian S J Blagg
Journal:  Eur J Med Chem       Date:  2017-10-18       Impact factor: 6.514

Review 4.  BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.

Authors:  Jaquelyn N Sanchez; Ton Wang; Mark S Cohen
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 5.  Proteomic interrogation of HSP90 and insights for medical research.

Authors:  Lorenz Weidenauer; Tai Wang; Suhasini Joshi; Gabriela Chiosis; Manfredo R Quadroni
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

6.  Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.

Authors:  Katherine M Byrd; Caitlin N Kent; Brian S J Blagg
Journal:  ChemMedChem       Date:  2017-11-30       Impact factor: 3.466

7.  Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads.

Authors:  Ilda D'Annessa; Sara Sattin; Jiahui Tao; Marzia Pennati; Carlos Sànchez-Martìn; Elisabetta Moroni; Andrea Rasola; Nadia Zaffaroni; David A Agard; Anna Bernardi; Giorgio Colombo
Journal:  Chemistry       Date:  2017-03-22       Impact factor: 5.236

8.  Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain.

Authors:  Stefania Terracciano; Alessandra Russo; Maria G Chini; Maria C Vaccaro; Marianna Potenza; Antonio Vassallo; Raffaele Riccio; Giuseppe Bifulco; Ines Bruno
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

9.  A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro.

Authors:  Chitra Subramanian; Rebecca Gorney; Ton Wang; Derek Ge; Nina Zhang; Ang Zuo; Brian S J Blagg; Mark S Cohen
Journal:  Surgery       Date:  2020-07-24       Impact factor: 3.982

10.  Novobiocin, a Newly Found TRPV1 Inhibitor, Attenuates the Expression of TRPV1 in Rat Intestine and Intestinal Epithelial Cell Line IEC-6.

Authors:  Qianying Liang; Xueli Lv; Qing Cai; Yun Cai; Boxin Zhao; Guofeng Li
Journal:  Front Pharmacol       Date:  2018-10-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.